Patents Examined by Brian E McDowell
  • Patent number: 10815204
    Abstract: The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.
    Type: Grant
    Filed: April 1, 2017
    Date of Patent: October 27, 2020
    Assignee: Honour (R&D)
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Bandi Vamsi Krishna, Kesireddy Subhash Chander Reddy, Kancharla Rajendar Reddy
  • Patent number: 10815217
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: October 27, 2020
    Assignee: Respivert Ltd.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Patent number: 10815241
    Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: October 27, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Hitoshi Ban, Naoaki Shimada, Wataru Hirose, Akihiko Arakawa, Kazuto Yamazaki, Kenjiro Hira
  • Patent number: 10813938
    Abstract: Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: October 27, 2020
    Assignee: AMRI SSCI, LLC
    Inventors: Shital Viral Mehta, Jing Teng, Jon Selbo
  • Patent number: 10807978
    Abstract: The present application relates to a process for the preparation of crystalline form A of palbociclib having specific surface area more than 2 m2/g comprising one-pot process for the preparation of compound of formula (IV). The present application further relates to the preparation of acid-addition salts of palbociclib and their use for the synthesis of crystalline form A of palbociclib having specific surface area more than 2 m2/g.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: October 20, 2020
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Andiappan Murugan, Vipinkumar Shriram Kabra, Chinna Saida Reddy Gade, Rama Rao Gondu, Shravankumar Chandrashekar, Krishnamoorthy Pasupathy, Anandan Kalaiselvan
  • Patent number: 10807994
    Abstract: Heterocyclic compounds of Formula (I): as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: October 20, 2020
    Assignee: NUVATION BIO INC.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Varun Kumar
  • Patent number: 10808129
    Abstract: The present invention relates to novel methine dyes, methods for the preparation thereof and use thereof for dyeing plastics, especially polyamides, so as to obtain yellow to orange colourings with improved light fastness and improved thermal stability. Methine dyes for example accord to the formula (I) in which R1 is hydrogen, halogen, alkyl, COOH or COOR9, R2 is oxygen or sulfur, R3 is hydrogen, halogen, COOH, COOR10 or CN, R4 is alkyl or phenyl, R5 and R6 are each independently alkyl, R7 and R8 are each independently hydrogen, halogen, alkyl or COOR11, and R9, R10 and R11 are each independently alkyl.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: October 20, 2020
    Assignee: LANXESS Deutschland GmbH
    Inventors: Hans-Ulrich Borst, Stephan Michaelis, Frank Linke
  • Patent number: 10799480
    Abstract: Calixpyrrole-based antitumor compounds such as compounds of Formula IX: are described, which can be derivatized to obtain their passive transport on tumor masses through the Enhanced Permeation and Retention, EPR, effect of the neoplastic vasculature. The conjugation of the above-mentioned compounds with peptides/antibodies is further described, for their possible active transport on tumor cells.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: October 13, 2020
    Assignee: Giam Pharma International SARL.
    Inventors: Franz Heinrich Kohnke, Alberto Izzotti, Camillo Rosano, Grazia Cafeo
  • Patent number: 10786492
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 29, 2020
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Patent number: 10787458
    Abstract: Disclosed is a novel chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines of Formula (I): or a solvate thereof. The novel chiral synthesis avoids the use of protection/deprotection steps.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 29, 2020
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil
  • Patent number: 10780102
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 22, 2020
    Assignee: VIIV HEALTHCARE UK (NO. 4) LIMITED
    Inventors: Sing-Yuen Sit, Yan Chen, Jie Chen, Jacob Swidorski, Brian Lee Venables, Ny Sin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Richard A. Hartz, Li Xu, Zheng Liu
  • Patent number: 10774083
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 15, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
  • Patent number: 10774074
    Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 15, 2020
    Assignee: ORION CORPORATION
    Inventors: Shouming Wang, Esa Kumpulainen, Jarmo Pystynen, Antti Pohjakallio, Anssi Haikarainen
  • Patent number: 10774045
    Abstract: Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: wherein X is absent, CH2, or C(O); R1 is H, OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino; R2 is H or C1-6 alkyl; R3 is H, C1-6 alkyl, —C(O)(C1-3 alkyl), or —C(O)O(C1-3 alkyl); R4 is C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R5 groups; and R5 is OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: September 15, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eugenia Trushina, Robert Greenhouse, Kevin Greenman, William Thomas
  • Patent number: 10758522
    Abstract: The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-?B essential modulator (“NEMO”) with I?B kinase-? (IKK-?) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 1, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Paul Robbins, Laura Niedernhofer, Theodore Kamenecka, Gabriela Mustata Wilson
  • Patent number: 10752613
    Abstract: Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels in blood or serum, for treating disorders of uric acid metabolism, and for maintaining normal uric acid levels in blood or serum are also provided. Pharmaceutical compositions comprising the bifunctional and monofunctional compounds are also provided.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 25, 2020
    Assignee: Acquist LLC
    Inventors: John J. Piwinski, Arshad Siddiqui, Raymond P. Warrell, Jr.
  • Patent number: 10752597
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 25, 2020
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • Patent number: 10752635
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 25, 2020
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
  • Patent number: 10745396
    Abstract: Polycyclic derivatives of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 18, 2020
    Assignee: Syngenta Participations AG
    Inventors: Pierre Joseph Marcel Jung, Andrew Edmunds, Michel Muehlebach
  • Patent number: 10745388
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 18, 2020
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Wenqing Yao